Compare HURN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HURN | ADPT |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 2004 | 2019 |
| Metric | HURN | ADPT |
|---|---|---|
| Price | $131.11 | $15.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $215.50 | $17.20 |
| AVG Volume (30 Days) | 236.8K | ★ 1.9M |
| Earning Date | 02-24-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.32 | N/A |
| EPS | ★ 5.98 | N/A |
| Revenue | ★ $1,618,977,000.00 | $276,976,000.00 |
| Revenue This Year | $14.19 | N/A |
| Revenue Next Year | $9.49 | $23.05 |
| P/E Ratio | $24.39 | ★ N/A |
| Revenue Growth | 12.67 | ★ 54.77 |
| 52 Week Low | $120.25 | $6.26 |
| 52 Week High | $186.78 | $20.76 |
| Indicator | HURN | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 19.70 | 35.51 |
| Support Level | $158.00 | $15.07 |
| Resistance Level | $176.10 | $17.98 |
| Average True Range (ATR) | 7.77 | 1.16 |
| MACD | -4.09 | -0.40 |
| Stochastic Oscillator | 3.11 | 13.13 |
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).